Rocket


Overview
Financials
News + Filings
Key Docs
Charts
Ownership
Insiders





All
All (ex-4s)
10-K
10-Q
8-K
3,4,5
Proxy
Prospectus
Other

Tags
Quarterly results
CC transcript
Director departure
Appointed director

VOLITIONRX LTD (VNRX) Create: Alert

All | News | Filings
Date FiledTypeDescription
08/14/2023 8-K Quarterly results
Docs: "VolitionRx Limited Announces Second Quarter 2023 Financial Results and Business Update Conference call to discuss financial and operational results scheduled for Tuesday, August 15, at 8:30 a.m. U.S. Eastern Time Henderson, Nevada, August 14, 2023 /PRNewswire/ -- VolitionRx Limited today announced financial results and a business update for the second quarter ended June 30, 2023. Volition management will host a conference call tomorrow, August 15 at 8:30 a.m. U.S. Eastern Time to discuss these results. Conference call details can be found below. "I am delighted to report that we submitted a Breakthrough Device Designation Request to the FDA in June for our Nu.Q ® technology in relation to sepsis. This was a milestone moment in our company’s history and for the first time we are in active ..."
06/30/2023 8-K Appointed a new director
Docs: "2015 Stock Incentive Plan, as amended"
05/10/2023 8-K Quarterly results
Docs: "VolitionRx Limited Announces First Quarter 2023 Financial Results and Business Update Conference call to discuss financial and operational results scheduled for Thursday, May 11, at 8:30 a.m. U.S. Eastern Time"
03/15/2023 8-K Results of Operations and Financial Condition, Financial Statements and Exhibits  Interactive Data
Docs: "VolitionRx Limited Announces Full Fiscal Year 2022 Financial Results and Business Update Conference call to discuss financial and operational results scheduled for Thursday, March 16, at 8:30 a.m. U.S. Eastern Time"
11/25/2022 8-K Quarterly results
11/14/2022 8-K Quarterly results
08/16/2022 8-K Quarterly results
08/10/2022 8-K Quarterly results
08/02/2022 8-K Entry into a Material Definitive Agreement, Results of Operations and Financial Condition, Other Events, Financial Statements...
Docs: "Underwriting Agreement, by and between VolitionRx Limited and Newbridge Securities Corporation",
"Opinion of Stradling, Yocca, Carlson & Rauth, P.ßC",
"VolitionRx Limited Announces Proposed Underwritten Public Offering of Common Stock HENDERSON, Nevada, July 28, 2022 /PRNewswire/ -- VolitionRx Limited , a multi-national epigenetics company, announced today that it has commenced an underwritten public offering of its common stock. All of the shares of common stock are being offered by Volition. In addition, Volition intends to grant the underwriter in the offering a 30-day option to purchase up to an additional 15% of the number of shares of common stock offered in the offering at the public offering price, less underwriting discounts and commissions. The final terms of the proposed offering will depend on market and other conditions, and there can be no assurance as to whether or when the offering may be completed, or as to the actual siz...",
"HENDERSON, Nevada, July 29, 2022 /PRNewswire/ -- VolitionRx Limited , a multi-national epigenetics company, announced today the pricing of its underwritten public offering of 3,000,000 shares of its common stock at a public offering price of $2.00 per share. The gross proceeds to Volition from the offering, before deducting the underwriting commissions and other estimated offering expenses payable by Volition, are expected to be $6 million. In addition, Volition has granted the underwriter in the offering a 30-day option to purchase up to an additional 450,000 shares of its common stock at the public offering price, less underwriting discounts and commissions, to cover over-allotments in connection with the offering. The offering is expected to close on or about August 2, 2022, subject to ...",
"HENDERSON, Nevada, August 2, 2022 /PRNewswire/ -- VolitionRx Limited , a multi-national epigenetics company, announced today the closing of its previously announced underwritten public offering of 3,450,000 shares of its common stock, including the exercise in full of the underwriter’s overallotment option, at a public offering price of $2.00 per share. The gross proceeds to Volition from the offering were $6.9 million, before deducting the underwriting commissions and other estimated offering expenses payable by Volition. All of the shares of common stock sold in the offering were offered by Volition. Volition intends to use the net proceeds from the offering for research and continued product development, clinical studies, product commercialization, working capital and other general corp..."
06/14/2022 8-K Quarterly results
05/20/2022 8-K Quarterly results
05/11/2022 8-K Quarterly results
03/30/2022 8-K Results of Operations and Financial Condition, Financial Statements and Exhibits  Interactive Data
Docs: "VolitionRx Limited Announces Full Fiscal Year 2021 Financial Results and Business Update Conference call to discuss financial and operational results scheduled for Thursday, March 31, at 8:00 am U.S. Eastern Time"
03/29/2022 8-K Entry into a Material Definitive Agreement, Regulation FD Disclosure, Financial Statements and Exhibits  Inte...
Docs: "AUSTIN, Texas, March 29, 2022 /PRNewswire/ --"
11/10/2021 8-K Quarterly results
Docs: "Conference call to discuss financial and operational results scheduled for Thursday, November 11, at 8:00 a.m. U.S. Eastern Time"
08/11/2021 8-K Quarterly results
Docs: "Conference call to discuss financial and operational results scheduled for Thursday, August 12, at 8:00 a.m. U.S. Eastern Time"
06/22/2021 8-K Quarterly results
05/11/2021 8-K Quarterly results
03/29/2021 8-K Quarterly results
03/22/2021 8-K Quarterly results
02/12/2021 8-K Quarterly results
02/09/2021 8-K Quarterly results
02/02/2021 8-K Quarterly results
01/15/2021 8-K Quarterly results
12/03/2020 8-K Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements...
Docs: "VolitionRx Limited Appoints Dr. Tom Butera DVM to Board of Directors AUSTIN, Texas, December 3, 2020 /PRNewswire/ -- VolitionRx Limited , a multi-national epigenetics company developing simple, easy to use, cost effective blood tests to help diagnose a range of cancers and other diseases in both humans and animals, announced today the appointment of Dr. Tom Butera DVM, to the Company’s Board of Directors, effective December 1, 2020. Dr. Butera was also appointed to the Company's Audit, Compensation and Nominations and Governance Committees. “We are pleased to welcome Tom to the Volition Board of Directors,” said Martin Faulkes, the Company’s Chairman of the Board. “Tom is a proven entrepreneur, innovator and value-based leader in the healthcare field, and we are confident he will bring a d..."
11/12/2020 8-K Quarterly results
Docs: "VolitionRx Limited Announces Third Quarter 2020 Financial Results and Business Update Conference call to discuss financial and operational results scheduled for Friday, November 13 at 8:30 a.m. U.S. Eastern Time"
08/13/2020 8-K Quarterly results
06/22/2020 8-K Quarterly results
05/22/2020 8-K Entry into a Material Definitive Agreement, Other Events, Financial Statements and Exhibits
Docs: "Underwriting Agreement, between the Company and National Securities Corporation, as representative of the several Underwriters named therein",
"Opinion of Stradling Yocca Carlson & Rauth, P.C",
"VolitionRx Announces Proposed Underwritten Public Offering of Common Stock AUSTIN, Texas, May 19, 2020 PRNewswire/ -- VolitionRx Limited , a multi-national epigenetics company that applies its Nucleosomics TM platform through its subsidiaries to develop simple, easy to use, cost-effective blood tests to help diagnose a range of cancers and other diseases, announced today that it intends to offer and sell shares of its common stock in an underwritten public offering. Volition intends to grant the underwriters a 30-day option to purchase additional shares of its common stock sold in the offering, to cover overallotments, if any. All shares of common stock in the offering are being offered by Volition. The proposed offering is subject to market and other conditions, and there can be no assura...",
"VolitionRx Announces Pricing of Underwritten Public Offering of Common Stock AUSTIN, Texas, May 20, 2020 PRNewswire/ -- VolitionRx Limited , a multi-national epigenetics company that applies its Nucleosomics TM platform through its subsidiaries to develop simple, easy to use, cost-effective blood tests to help diagnose a range of cancers and other diseases, announced today the pricing of its previously announced underwritten public offering. Volition is offering 4,365,000 shares of common stock, par value $0.001 per share, at a price to the public of $2.75 per share. In connection with the offering, Volition has also granted the underwriters a 30-day option to purchase up to an additional 654,750 shares of its common stock offered in the public offering, at the same public offering price p...",
"VolitionRx Announces Closing of $13.8 Million Public Offering of Common Stock AUSTIN, Texas, May 22, 2020 PRNewswire/ -- VolitionRx Limited , a multi-national epigenetics company that applies its Nucleosomics TM platform through its subsidiaries to develop simple, easy to use, cost-effective blood tests to help diagnose a range of cancers and other diseases, announced today the closing of its previously announced underwritten public offering of an aggregate of 5,019,750 shares of common stock, including the exercise in full of the overallotment option, at a public offering price of $2.75 per share for total gross proceeds of $13.8 million, before deducting underwriting discounts, commissions and estimated offering expenses payable by Volition. All of the shares of common stock sold in the ..."
05/07/2020 8-K Quarterly results
04/23/2020 8-K Regulation FD Disclosure, Financial Statements and Exhibits
Docs: "Volition Files Patent for Nu.Q TM COVID-19 Triage Test and Commences Proof of Concept Studies AUSTIN, Texas, April 23, 2020 /PRNewswire/ -- VolitionRx Limited today announced that it is actively developing a COVID-19 triage test aiming to predict the likelihood that an individual who is COVID-19 positive will develop complications and severe disease, using its propriety Nu.Q TM platform. The goal of the test is to provide early insight into which patients may require higher levels of monitoring including hospitalization and critical care resources, versus those who will not develop serious symptoms. Preliminary studies of patients with COVID-19 infection are now underway in hospitals in Belgium and Germany with results expected this quarter. An interview with Jake Micallef, Chief Scientif..."
02/20/2020 8-K Quarterly results
11/12/2019 8-K Quarterly results
10/09/2019 8-K Quarterly results
  Next >>

Rocket Data Systems, Inc. © 2019 | Contact Us | Data Disclaimer | Terms of Use | Privacy